Filing search / Material / Tenax Therapeutics, Inc. / Page 3

8-K

EX-10.1

lp43p

13 Mar 20

Tenax Therapeutics Announces $2.75 Million Registered Direct Offering Priced At-the-Market

8:16am

8-K

EX-10.1

mi4evdm

5 Jun 18

Tenax Therapeutics Announces Appointment of

4:45pm

8-K

EX-10.1

hu7i2is077ega bnru

7 Apr 17

Tenax Therapeutics Announces Review of Strategic Alternatives and Business Update

12:00am

10-KT

EX-10.74

ypsep ac8cc94

14 Mar 16

Annual report (with FYE transition)

12:00am

8-K

EX-10.1

btgibnd2eceiz

19 Jun 15

Departure of Directors or Certain Officers

12:00am

8-K

EX-10.2

6th49xcvolnkbgals

19 Jun 15

Departure of Directors or Certain Officers

12:00am

424B3

EX-10.4

65jom kplq5bnf

24 Mar 14

Prospectus supplement

12:00am